<DOC>
	<DOCNO>NCT00797862</DOCNO>
	<brief_summary>This study compare safety efficacy initial combination treatment aliskiren + amlodipine sequential add-on treatment strategy aliskiren amlodipine patient hypertension .</brief_summary>
	<brief_title>Aliskiren Calcium Channel Blocker Amlodipine Combination Initial Treatment Strategy Hypertension</brief_title>
	<detailed_description>This study design evaluate patient hypertension treat early combination therapy would achieve good blood pressure ( BP ) control , patient treat classical sequential add-on therapy . The study compare effect two treatment strategy : Treatment initiation single compound , either aliskiren amlodipine , continuation combination versus treatment initiation combination aliskiren/amlodipine continuation combination . The study also evaluate overall mean sit systolic blood pressure ( msSBP ) -lowering effect study , well change baseline study end msSBP , superior group receive combination therapy beginning . The study evaluate BP-lowering efficacy tolerability treatment strategy .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Calcium Channel Blockers</mesh_term>
	<criteria>Male female outpatient ≥ 18 year age Participants essential hypertension : Naive participant must mean sit Systolic Blood Pressure ( msSBP ) ≥ 150 mmHg &lt; 180 mmHg Visit 1 Visit 2 . ( Participants consider 'naïve ' never treat antihypertensive medication . ) All participant must msSBP ≥ 150 mmHg &lt; 180 mmHg Visit 2 Written inform consent participate study prior study procedure Severe hypertension Pregnant nursing ( lactate ) woman Premenopausal woman take accepted form birth control Serum potassium ≥ 5.5 mEq/L ( mmol/L ) Visit 1 History cardiovascular condition Uncontrolled Type 1 Type 2 diabetes mellitus Hypersensitivity renin inhibitor , calcium channel blocker , drug similar chemical structure Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Aliskiren</keyword>
	<keyword>Amlodipine</keyword>
	<keyword>Hypertension</keyword>
	<keyword>SPA1000</keyword>
	<keyword>Norvasc</keyword>
</DOC>